[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100562326":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":39,"centralContacts":44,"locations":54,"responsibleParty":86,"collaborators":88,"id":102,"slug":103,"hasResults":104,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":104,"sex":110,"minAge":30,"maxAge":111,"enrollmentInfo":112,"targetDuration":30,"studyType":115,"phases":116,"briefSummary":118,"conditions":119,"keywords":122,"overallStatus":74,"whyStopped":30,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":146},{"fullName":5,"class":6},"Institut de Recherche Clinique du Benin","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm A","EXPERIMENTAL","All PDMC drugs will be given to the caregivers at discharge with reminder support",[13],"Other: Adherence support strategy A",{"label":15,"type":10,"description":16,"interventionNames":17},"Arm B","All PDMC drugs will be given by the community health workers (CHWs) to the caregivers at home, with reminder support",[18],"Other: Adherence support strategy B",{"label":20,"type":21,"description":22,"interventionNames":23},"Arm C","ACTIVE_COMPARATOR","All PDMC drugs will be given to the caregivers at discharge with no other adherence support approaches (no reminder)",[24],"Other: Control",[26,31,35],{"type":6,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"Adherence support strategy A","Community health worker (CHW) support through monthly home visits to remind the caregiver to administrate the PDMC drugs",[9],null,{"type":6,"name":32,"description":33,"armGroupLabels":34,"otherNames":30},"Adherence support strategy B","SMS\u002Fphone reminders from the qualified community health officers (ASCQ) to the community health workers (CHW) to administrate the PDMC drugs",[15],{"type":6,"name":36,"description":37,"armGroupLabels":38,"otherNames":30},"Control","No reminders",[20],[40],{"name":41,"affiliation":42,"role":43},"Jenny Hill, MSc, PhD","Liverpool School of Tropical Medicine","PRINCIPAL_INVESTIGATOR",[45,50],{"name":46,"role":47,"phone":48,"phoneExt":30,"email":49},"Manfred Accrombessi, MD, PhD","CONTACT","22966033138","accrombessimanfred@gmail.com",{"name":51,"role":47,"phone":52,"phoneExt":30,"email":53},"Achille Massougbodji, MD","22996807027","massougbodjiachille@yahoo.fr",[55,72],{"facility":56,"status":57,"city":58,"state":30,"zip":30,"country":59,"countryCode":60,"cosmosGeoPoint":61,"geoPoint":66,"contacts":67},"Goho Departmental Hospital Centre","NOT_YET_RECRUITING","Abomey","Benin","BJ",{"type":62,"coordinates":63},"Point",[64,65],1.99119,7.18286,{"lat":65,"lon":64},[68],{"name":69,"role":47,"phone":70,"phoneExt":30,"email":71},"Natacha Nouwakpo, MD","22996354034","nnouwakpo@gmail.com",{"facility":73,"status":74,"city":75,"state":30,"zip":30,"country":59,"countryCode":60,"cosmosGeoPoint":76,"geoPoint":80,"contacts":81},"Centre Hospitalier Universitaire de la Mere et de l'Enfant Lagune (CHU-MEL)","RECRUITING","Cotonou",{"type":62,"coordinates":77},[78,79],2.41833,6.36536,{"lat":79,"lon":78},[82],{"name":83,"role":47,"phone":84,"phoneExt":30,"email":85},"Jules Alao, MD","+2290197480733","amomj@yahoo.fr",{"type":87,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR",[89,90,92,94,97,100],{"name":42,"class":6},{"name":91,"class":6},"Kenya Medical Research Institute",{"name":93,"class":6},"Epicentre, Paris, France and Mbarara University of Science and Technology, Faculty of Medicine, Mbarara, Uganda",{"name":95,"class":96},"Institut de Recherche pour le Developpement","OTHER_GOV",{"name":98,"class":99},"Training Research Unit of Excellence, Blantyre, Malawia","UNKNOWN",{"name":101,"class":6},"Centres for Disease Control and Prevention, Kenya.","100562326","phase-4-post-discharge-malaria-chemoprevention-implementation-trial-in-benin-100562326",false,"NCT06601712","Post-discharge Malaria Chemoprevention Implementation Trial in Benin","Delivery Strategies for Malaria Chemoprevention in the Post-discharge Management of Children Hospitalised With Severe Anaemia or Severe Malaria: a Cluster Randomised Controlled Implementation Trial in Benin","PDMC-SL","Inclusion Criteria:\n\n* Aged below 10 years of both sexes\n* Hospitalised with severe anaemia or severe malaria: Initially hospitalised with haemoglobin below 5.0 g\u002Fdl or PCV below 15%, or requirement for blood transfusion for other clinical reasons on or during admission to the hospital, or severe malaria, defined as a requirement for parenteral artesunate in the opinion of the treating clinician and the presence of microscopy or RDT confirmed Plasmodium infection\n\nExclusion Criteria:\n\n* Recognised specific other causes of severe anaemia (i.e., trauma, haematological malignancy, known bleeding disorders, such as haemophilia)\n* Sickle cell anaemia\u002Fsickle cell disease\n* Body weight below 5 kg\n* HIV infection and cotrimoxazole prophylaxis are not exclusion criteria","ALL","9 Years",{"count":113,"type":114},648,"ESTIMATED","INTERVENTIONAL",[117],"PHASE4","The proposed research aims to conduct implementation trials in Benin, co-designed with national stakeholders, to evaluate different delivery strategies for optimizing health system delivery of post-discharge malaria chemoprevention (PDMC) drugs and adherence to PDMC. This chemoprevention strategy is effective in reducing hospital readmissions and deaths after discharge. However, there is no clear delivery platform for PDMC, and adherence to the 3-day dosing regimen, provided monthly three times after discharge, is a potential limitation. The current trial will provide evidence-based data on acceptability, feasibility, and cost-effectiveness to aid decision-makers. The evidence generated will be used to support the effective implementation and scale-up of PDMC in high malaria-endemic areas such as Benin.",[120,121],"Severe Malaria","Severe Anaemia",[123,124,125,126,127,128,129,130,131,132,133,59,134,135,136],"Children","Antimalarial","Prevention","Chemoprevention","Caregivers","Patient discharge","Health care providers","Health economics","Qualitative research","Feasibility","Cost-effectiveness","Artemisinins","School age","Pre-school","2025-07-21",{"date":139,"type":140},"2025-07-24","ACTUAL",{"date":142,"type":140},"2025-07-02",{"date":144,"type":114},"2026-12-31",{"name":5,"class":6},2]